http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103823066-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 |
| filingDate | 2014-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103823066-B |
| titleOfInvention | For lung cancer early metaphase quick diagnosis reagent kit and its detection method |
| abstract | The invention discloses one kind to be used for lung cancer early metaphase quick diagnosis reagent kit, and the capture antibody includes galactose agglutinin, cytokeratin fragment antigen 21 1 and monoclonal antibody made from human aspartyl's B-hydroxylase difference；The kit also includes detection antibody, and the detection antibody includes the polyclonal antibody after galactose agglutinin, cytokeratin fragment antigen 21 1 and HRP marks made from human aspartyl's B-hydroxylase difference.Beneficial effects of the present invention are as follows：With high sensitivity accuracy it is strong the characteristics of, its sensitivity and accuracy reach more than 90%, can effectively reduce in addition testing cost, reduce operating procedure and reduce detection error. |
| priorityDate | 2014-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.